Last reviewed · How we verify
DAA treatment
At a glance
| Generic name | DAA treatment |
|---|---|
| Also known as | Treatment with direct-acting antiviral agents |
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (PHASE1)
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (NA)
- The Kentucky Viral Hepatitis Treatment Study (PHASE4)
- Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy (PHASE4)
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania (EARLY_PHASE1)
- Comparative Study on Surgical Approaches for Elderly Femoral Neck Fractures (NA)
- The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an
- Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |